PK/PD Studies Should Routinely Include Women, FDA Says
Executive Summary
Women should be routinely included in pharmacokinetic and pharmacodynamic studies performed in Phase I and II trials, FDA said April 18.
You may also be interested in...
Women Enrollment In Phase I/II Trials Continues To Be Low, GAO Says
Women continue to be under-represented in early phase safety studies, a General Accounting Office report on women in clinical trials suggests.
Women Enrollment In Phase I/II Trials Continues To Be Low, GAO Says
Women continue to be under-represented in early phase safety studies, a General Accounting Office report on women in clinical trials suggests.
FDA Standardized NDA Review Format Includes Gender Analysis
Gender analysis is a required component of FDA's newly instituted standardized format for NDA reviews, the agency said April 18.